Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01228305 · ClinicalTrials.gov registry record · NA
Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass
A NA study of Congenital Heart Disease and Cardiopulmonary Bypass, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01228305: Completed NA study of Congenital Heart Disease and Cardiopulmonary Bypass, sponsored by Vanderbilt University Medical Center.
NCT01228305 is a NA study of Congenital Heart Disease and Cardiopulmonary Bypass that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 30 participants, below the 474-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01228305, a NA study of Congenital Heart Disease and Cardiopulmonary Bypass, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The current proposal tests the central hypothesis that acetaminophen will attenuate the oxidative stress response associated with cardiopulmonary bypass (CPB)-induced hemolysis in children undergoing cardiac surgery.
Primary Outcome
Test the hypothesis that acetaminophen attenuates the oxidative stress response, as measured by F2-isoprostanes, in children undergoing cardiopulmonary bypass. The primary outcome is the oxidative stress response as measured by F2-isoprostane
Conditions Studied
Interventions
- OTHER Acetaminophen
Study Locations (1)
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-03 |
| Phase | NA |
What the finished NCT01228305 record still lists
NCT01228305 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 474-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Acetaminophen is the first listed.
NCT01228305 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01228305 about?
NCT01228305 is a clinical study titled "Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass". The current proposal tests the central hypothesis that acetaminophen will attenuate the oxidative stress response associated with cardiopulmonary bypass (CPB)-induced hemolysis in children undergoing cardiac surgery.
What is the current status of trial NCT01228305?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2011-07. Estimated completion is 2014-03.
What conditions does trial NCT01228305 study?
This clinical trial studies the following conditions: Congenital Heart Disease, Cardiopulmonary Bypass.
What interventions are being tested in trial NCT01228305?
The interventions under investigation include: Acetaminophen (OTHER).
Who is sponsoring clinical trial NCT01228305?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01228305 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01228305's enrollment target sits among peer trials
30 56th of 63 higher than 7 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fontan Fitness Trial
RECRUITING · NA
-
Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery
RECRUITING · NA
-
The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study
RECRUITING · NA
-
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
RECRUITING · NA
-
A Study of Hemodynamic Cardiopulmonary Exercise for CHD
RECRUITING · NA
-
Ventripoint Single Ventricle Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia